Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lotte Kaasenbrood

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Circulation|March 29, 2017
Response by Kaasenbrood et al to Letter Regarding Article, "Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population"Lotte Kaasenbrood, Yolanda van der Graaf, Frank L J Visseren
Nederlands Tijdschrift Voor Geneeskunde|July 18, 2013
[Acute liver injury in a patient with anorexia nervosa]Lotte Kaasenbrood, Jurjen J Boonstra, Mark F J Stolk, et al.
Nederlands Tijdschrift Voor Geneeskunde|June 18, 2024
[To what extent does the eGFR reflects renal function?]Robin W M Vernooij, Lotte Kaasenbrood, Femke Kaasenbrood, et al.
Nephron|March 6, 2024
Medullary Sponge Kidney and Its Relationship with Primary Distal Renal Tubular Acidosis: Case Reports and a Comprehensive Genetics-First ApproachGerrit van den Berg, Laura R Claus, Bert van der Zwaag, et al.
Kidney360|April 25, 2024
Polypharmacy in Patients with CKD: A Systematic Review and Meta-AnalysisIlse J Oosting, Julia M T Colombijn, Lotte Kaasenbrood, et al.
BMJ (Clinical Research Ed.)|April 1, 2016
How to translate clinical trial results into gain in healthy life expectancy for individual patientsJannick A N Dorresteijn, Lotte Kaasenbrood, Nancy R Cook, et al.
Heart (British Cardiac Society)|April 7, 2018
Estimated individual lifetime benefit from PCSK9 inhibition in statin-treated patients with coronary artery diseaseLotte Kaasenbrood, Kausik K Ray, S Matthijs Boekholdt, et al.
Diabetes Technology & Therapeutics|November 2, 2012
Advanced glycation end products, measured as skin autofluorescence, during normal pregnancy and pregnancy complicated by diabetes mellitusWendela L de Ranitz-Greven, Lotte Kaasenbrood, Wendy K Poucki, et al.
Circulation. Cardiovascular Quality and Outcomes|May 14, 2016
Development and Validation of a Model to Predict Absolute Vascular Risk Reduction by Moderate-Intensity Statin Therapy in Individual Patients With Type 2 Diabetes Mellitus: The Anglo Scandinavian Cardiac Outcomes Trial, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, and Collaborative Atorvastatin Diabetes StudyLotte Kaasenbrood, Neil R Poulter, Peter S Sever, et al.
Journal of the American Heart Association|October 30, 2018
Estimated Life Expectancy Without Recurrent Cardiovascular Events in Patients With Vascular Disease: The SMART-REACH ModelLotte Kaasenbrood, Deepak L Bhatt, Jannick A N Dorresteijn, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Circulation|March 29, 2017
Response by Kaasenbrood et al to Letter Regarding Article, "Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population"Lotte Kaasenbrood, Yolanda van der Graaf, Frank L J Visseren
Nederlands Tijdschrift Voor Geneeskunde|July 18, 2013
[Acute liver injury in a patient with anorexia nervosa]Lotte Kaasenbrood, Jurjen J Boonstra, Mark F J Stolk, et al.
Nederlands Tijdschrift Voor Geneeskunde|June 18, 2024
[To what extent does the eGFR reflects renal function?]Robin W M Vernooij, Lotte Kaasenbrood, Femke Kaasenbrood, et al.
Nephron|March 6, 2024
Medullary Sponge Kidney and Its Relationship with Primary Distal Renal Tubular Acidosis: Case Reports and a Comprehensive Genetics-First ApproachGerrit van den Berg, Laura R Claus, Bert van der Zwaag, et al.
Kidney360|April 25, 2024
Polypharmacy in Patients with CKD: A Systematic Review and Meta-AnalysisIlse J Oosting, Julia M T Colombijn, Lotte Kaasenbrood, et al.
BMJ (Clinical Research Ed.)|April 1, 2016
How to translate clinical trial results into gain in healthy life expectancy for individual patientsJannick A N Dorresteijn, Lotte Kaasenbrood, Nancy R Cook, et al.
Heart (British Cardiac Society)|April 7, 2018
Estimated individual lifetime benefit from PCSK9 inhibition in statin-treated patients with coronary artery diseaseLotte Kaasenbrood, Kausik K Ray, S Matthijs Boekholdt, et al.
Diabetes Technology & Therapeutics|November 2, 2012
Advanced glycation end products, measured as skin autofluorescence, during normal pregnancy and pregnancy complicated by diabetes mellitusWendela L de Ranitz-Greven, Lotte Kaasenbrood, Wendy K Poucki, et al.
Circulation. Cardiovascular Quality and Outcomes|May 14, 2016
Development and Validation of a Model to Predict Absolute Vascular Risk Reduction by Moderate-Intensity Statin Therapy in Individual Patients With Type 2 Diabetes Mellitus: The Anglo Scandinavian Cardiac Outcomes Trial, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, and Collaborative Atorvastatin Diabetes StudyLotte Kaasenbrood, Neil R Poulter, Peter S Sever, et al.
Journal of the American Heart Association|October 30, 2018
Estimated Life Expectancy Without Recurrent Cardiovascular Events in Patients With Vascular Disease: The SMART-REACH ModelLotte Kaasenbrood, Deepak L Bhatt, Jannick A N Dorresteijn, et al.
Pageof 2